It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Activated hepatic stellate cells (HSCs) are significant in liver fibrosis. Our past investigations have shown that human umbilical cord mesenchymal stem cells (hucMSCs) and their secreted exosomes (MSC-ex) could alleviate liver fibrosis via restraining HSCs activation. However, the mechanisms underlying the efficacy were not clear. Ferroptosis is a regulatory cell death caused by excessive lipid peroxidation, and it plays a vital role in the occurrence and development of liver fibrosis. In the present study, we aimed to study the proferroptosis effect and mechanism of MSC-ex in HSCs. MSC-ex were collected and purified from human umbilical cord MSCs. Proferroptosis effect of MSC-ex was examined in HSCs line LX-2 and CCl4 induced liver fibrosis in mice. Gene knockdown or overexpression approaches were used to investigate the biofactors in MSC-ex-mediated ferroptosis regulation. Results: MSC-ex could trigger HSCs ferroptosis by promoting ferroptosis-like cell death, ROS formation, mitochondrial dysfunction, Fe2+ release, and lipid peroxidation in human HSCs line LX-2. Glutathione peroxidase 4 (GPX4) is a crucial regulator of ferroptosis. We found that intravenous injection of MSC-ex significantly decreased glutathione peroxidase 4 (GPX4) expression in activated HSCs and collagen deposition in experimental mouse fibrotic livers. Mechanistically, MSC-ex derived BECN1 promoted HSCs ferroptosis by suppressing xCT-driven GPX4 expression. In addition, ferritinophagy and necroptosis might also play a role in MSC-ex-promoted LX-2 cell death. Knockdown of BECN1 in MSC diminished proferroptosis and anti-fibrosis effects of MSC-ex in LX-2 and fibrotic livers. MSC-ex may promote xCT/GPX4 mediated HSCs ferroptosis through the delivery of BECN1 and highlights BECN1 as a potential biofactor for alleviating liver fibrosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 The Third Hospital of Zhenjiang Affiliated Jiangsu University, School of Medicine, Jiangsu University, Zhenjiang, PR China (GRID:grid.440785.a) (ISNI:0000 0001 0743 511X)
2 Jiangsu University, Key Laboratory of Laboratory Medicine of Jiangsu Province, School of Medicine, Zhenjiang, PR China (GRID:grid.440785.a) (ISNI:0000 0001 0743 511X); The Second Affiliated Hospital of Soochow University, Suzhou, PR China (GRID:grid.452666.5) (ISNI:0000 0004 1762 8363)
3 Jiangsu University, Key Laboratory of Laboratory Medicine of Jiangsu Province, School of Medicine, Zhenjiang, PR China (GRID:grid.440785.a) (ISNI:0000 0001 0743 511X)
4 The Third Hospital of Zhenjiang Affiliated Jiangsu University, School of Medicine, Jiangsu University, Zhenjiang, PR China (GRID:grid.440785.a) (ISNI:0000 0001 0743 511X); Jiangsu University, Key Laboratory of Laboratory Medicine of Jiangsu Province, School of Medicine, Zhenjiang, PR China (GRID:grid.440785.a) (ISNI:0000 0001 0743 511X)